LONGITUDINAL FOLLOW-UP OF SARS-COV-2 IMMUNITY IN IMMUNOCOMPROMISED POPULATIONS IN BELGIUM (COVICO) A non-commercial multicenter academic prospective cohort study during 2023-2026

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518098-33-01

Enrollment

360

Registered

2024-11-25

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy persons and immunocompromised patients (nursing home residents, dialysis patients and kidney- and lung transplant patients) from age 18 till age 105

Brief summary

To assess the level of binding and neutralizing antibodies against the epidemiologically predominant SARS-CoV-2 variant of concern (VOC) three times a year

Detailed description

Secondary objectives include studying the vaccine induced immunity in more detail. This includes the further characterization of the quality of the antibody response and the measurement of the cellular immune response, amongst others.

Interventions

DRUGComirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine

DRUGComirnaty JN.1 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To assess the level of binding and neutralizing antibodies against the epidemiologically predominant SARS-CoV-2 variant of concern (VOC) three times a year	—

Secondary

Measure	Time frame
Secondary objectives include studying the vaccine induced immunity in more detail. This includes the further characterization of the quality of the antibody response and the measurement of the cellular immune response, amongst others.	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026